EQT to Acquire Qiagen in $10.8 Billion Molecular Testing Deal
EQT will acquire Qiagen for €9.6B ($10.78B), with a premium of 8.6% per share. The deal includes participation from Abu Dhabi Investment Authority and Canada Pension Plan Investment Board. Qiagen's shares rose 0.7% in extended trading. The transaction, valued at $12.1B including debt, is expected to close in mid-2027. Qiagen's board approved the offer, citing it as the best path forward.
How this was made
The 30-second read
Why it matters
The deal adds a strategic platform for EQT and provides Qiagen shareholders a premium exit, likely driving short‑term upside.
Market read
The announcement is a primary, material M&A event that moves Qiagen stock and signals broader sector consolidation.
What to watch
Potential integration challenges and the impact of debt financing on Qiagen's balance sheet.
Background
EQT, a Swedish private‑equity firm, is expanding its footprint in the molecular diagnostics space by acquiring Qiagen, a Dutch‑origin biotech listed in the US.
Ticker impact
Qiagen shares rose 0.7% in extended trading after EQT announced a $10.8 billion acquisition offer.
upward pressure as the market prices in the 8.6% premium and deal certainty
Deal is newly disclosed, sizable, and includes a clear premium; investors typically bid up target shares on such news.
Market effects
Consolidation in the molecular testing and diagnostics sector may spur further M&A activity.
European private‑equity activity gains visibility, potentially influencing other European biotech valuations.
Large‑cap biotech investors worldwide will reassess valuations of similar companies.
Counterpoint
If regulatory hurdles or financing issues arise, the deal could collapse, pressuring Qiagen lower.
Key entities
- private equity firmEQT
Swedish buyout firm leading the acquisition.
- biotech companyQiagen
US‑listed molecular testing company being acquired.

